ABSTRACT
E-cigarettes and vaping products were first introduced in the United States around 2007, and quickly grew in popularity. By 2014, e-cigarettes had become the most commonly used tobacco product among youth in the United States. An e-cigarette, or vaping, product use-associated lung injury (EVALI) outbreak was identified by the Centers for Disease Control and Prevention (CDC) in 2019, with many cases in the adolescent population. The CDC opened a national database of cases and launched a multistate investigation; reported cases reached a peak in September 2019. The CDC investigation found that a vaping liquid additive, vitamin E acetate, was strongly linked to the EVALI outbreak but determined that the decline in cases was likely multifactorial. Due to decreased cases and the identification of a potential cause of the outbreak, the CDC stopped collecting data on EVALI cases as of February 2020. However, e-cigarettes and vaping products have continued to be the most popular tobacco product among youth, though state and national regulations on these products have increased since 2016. While pediatric case series and studies have shown differences in clinical presentation and medical histories between pediatric and adult EVALI cases, the fact that cases are no longer tracked at a national level limits necessary information for pediatric clinicians and researchers. We describe the available literature on the diagnosis, pathophysiology, treatment, and outcomes of EVALI in the pediatric population, and provide clinical and public health recommendations to facilitate prevention and management of EVALI specific to pediatrics.
Subject(s)
Electronic Nicotine Delivery Systems , Lung Injury , Vaping , Humans , Vaping/adverse effects , Vaping/epidemiology , Lung Injury/epidemiology , Lung Injury/etiology , United States/epidemiology , Adolescent , Child , Disease Outbreaks , Centers for Disease Control and Prevention, U.S. , Public HealthABSTRACT
Despite growing recognition of the need for increased diversity among students, trainees, and faculty in health care, the medical workforce still lacks adequate representation from groups historically underrepresented in medicine (URiM). The subspecialty field of pediatric pulmonology is no exception. Although there have been efforts to address issues of diversity, equity, and inclusion (DEI) in our own field, gaps persist. To address these gaps, the members of the Diversity, Equity, and Inclusion Advisory Group (DEI-AG) of the American Thoracic Society Pediatrics Assembly created and distributed a Needs Assessment Survey in the United States and Canada to better understand the racial and ethnic demographics of the pediatric pulmonary workforce and to learn more about successes, gaps, and opportunities to enhance how we recruit, train, and retain a diverse workforce. The DEI-AG leadership cochairs convened a workshop to review the findings of the DEI Needs Assessment Survey and to develop strategies to improve the recruitment and retention of URiM fellows and faculty. This Official ATS Workshop Report aims to identify barriers and opportunities for recruitment, training, and career development within the field of pediatric pulmonology. Additionally, we offer useful strategies and resources to improve the recruitment of URiM residents, the mentorship of trainees and junior faculty, and the career development of URiM faculty in academic centers. This Workshop Report is an important first deliverable by the DEI-AG. We hope that this work, originating from within the Pediatrics Assembly, will serve as a model for other Assemblies, disciplines across the ATS, and other fields in Pediatrics.
ABSTRACT
Hybrid lesions (HLs) are unique, congenital lung malformations with both cystic and solid components and vascular supply consistent with bronchopulmonary sequestration. Increase of HLs reported in recent literature suggest a common pathological mechanism occurring during embryogenesis, leading to occurrence of both malformations within a single lesion. Due to the unusual nature of HLs, gold standard approach for diagnosis is not very well-defined in the literature. We report a novel case of a 3-year-old girl with posterior fossa anomalies-haemangioma-arterial lesions-coarctation of the aorta-eye anomalies syndrome, who was found, on CT angiography, to have a previously missed HL diagnosis which was confirmed after surgical resection.
Subject(s)
Aortic Coarctation/complications , Eye Abnormalities/complications , Lung/abnormalities , Neurocutaneous Syndromes/complications , Child, Preschool , Female , Humans , Incidental Findings , Lung/diagnostic imaging , PhenotypeSubject(s)
Environmental Exposure , Farms , Respiratory Tract Diseases/epidemiology , Respiratory Tract Diseases/etiology , Age Factors , Child, Preschool , Disease Susceptibility , Humans , Public Health Surveillance , Respiratory Tract Diseases/diagnosis , Risk Assessment , Risk Factors , Severity of Illness Index , Wisconsin/epidemiologyABSTRACT
BACKGROUND: Depression is common in cystic fibrosis (CF) and linked with worse outcomes during hospitalization. Bright-light therapy during hospitalizations augments antidepressant regimens and reduces length of stay (LOS) in depressed non-CF patients, but has not been examined in CF METHODS: Thirty subjects used a light box emitting 10,000lx for 30min each day for 7 straight days following hospital admission for pulmonary exacerbation. Depressive symptom severity (QIDS-C) and quality of life factors (CFQ-R) were recorded pre/post light therapy. RESULTS: Eighty percent of subjects had at least mild depressive symptoms upon admission. Hospitalized CF patients had a significantly lower mean LOS of 11.0±3.6 days compared to a historical cohort from the year prior (13.3±4.4 days, p value=0.038). There was a significant decrease in depressive symptoms for all subjects receiving light therapy (p value<0.0001). There was no relation between depressive symptoms and lung function or vitamin D. Six out of twelve quality of life indicators improved with light therapy including the domains of vitality, emotion, and health perceptions. There were no adverse events reported. LIMITATIONS: As a pilot study, the design was limited by a lack of a control group and possible confounding effects of hospitalization treatment on systemic symptoms. CONCLUSIONS: Light therapy was well tolerated by hospitalized CF patients and resulted in improved depressive symptoms and quality of life. Light therapy was associated with a reduced length of stay. Large, randomized trials of light therapy may be indicated for hospitalized CF patients.
Subject(s)
Cystic Fibrosis/complications , Cystic Fibrosis/therapy , Depression/complications , Depression/therapy , Phototherapy , Adult , Female , Hospitalization , Humans , Length of Stay , Male , Pilot Projects , Quality of Life , Young AdultABSTRACT
Aortic aneurysmal diseases, mostly found incidentally, have high mortality and morbidity. Complications mostly are associated with and accelerated in the presence of systemic hypertension, aortic valve disease, or aortic atherosclerosis. Presenting signs and symptoms can be nonspecific and need immediate and accurate recognition. We present a case of incidental finding of a large descending aortic aneurysm with "yin-yang" sign and discuss the importance of differentiating pseudoaneurysm versus intramural thrombus.
Subject(s)
Aortic Aneurysm, Thoracic/complications , Dyspnea/etiology , Aged, 80 and over , Aortic Aneurysm, Thoracic/diagnosis , Aortic Aneurysm, Thoracic/drug therapy , Aortic Rupture/etiology , Aortography/methods , Dyspnea/diagnosis , Fatal Outcome , Female , Humans , Predictive Value of Tests , Time Factors , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
We report the case of a patient who presented with a 3-month history of random epistaxis and recent onset of acute hearing loss associated with fever, chills, and myalgias. Pure tone audiometry revealed bilateral sensorineural hearing loss. Complete blood cell count showed an abnormal neutrophil count of 700/uL (normal >1900/microL) and platelet count of 25 x 10(3)/microL (normal >175 x 10(3)/microL). Giemsa-stained peripheral blood smear revealed neutrophilic intracytoplasmic inclusion consistent with anaplasma morulae. Polymerase chain reaction confirmed Anaplasma phagocytophilum. The patient was treated with oral doxycycline, and, after 14 days of treatment, the hearing loss had improved markedly. Therefore, we concluded that the patient's acute transient bilateral sensorineural hearing loss was associated with anaplasmosis.
Subject(s)
Anaplasma phagocytophilum , Ehrlichiosis/diagnosis , Hearing Loss, Sensorineural/microbiology , Acute Disease , Anti-Bacterial Agents/therapeutic use , Audiometry, Pure-Tone , Diagnosis, Differential , Ehrlichiosis/drug therapy , Female , Humans , Middle AgedABSTRACT
Nephrogenic systemic fibrosis (NSF) is a scleroderma-like systemic fibrosing condition of unknown etiology described in patients with renal insufficiency. Gadolinium exposure has been strongly associated with the development of NSF though the mechanism of such injury is not known. There are only few reported cases of NSF in the setting of acute renal failure and fewer reported cases where skin lesions developed after kidney function had returned to normal. We report a case of NSF in a young Hispanic woman with lupus nephritis but normal creatinine, who received gadolinium during a brief episode of prerenal acute kidney injury not requiring dialysis, secondary to sepsis.